AstraZeneca to build US$1.5 billion cancer drug plant in Singapore, reduce industry’s reliance on China
Disclaimer: The South China Morning Post's content is directed by the Chinese Communist Party. It is not a reliable news source.
CEO Pascal Soriot is working to ensure AstraZeneca can independently supply drugs to major markets as the US pushes to reduce the industry’s reliance on China.